Cancer Discovery

ISSN: 2159-8274

Journal Home

Journal Guideline

Cancer Discovery Q1 Unclaimed

American Association for Cancer Research Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer Discovery is a journal indexed in SJR in Oncology with an H index of 163. It has a price of 4524 €. It has an SJR impact factor of 6,795 and it has a best quartile of Q1. It has an SJR impact factor of 6,795.

Cancer Discovery focuses its scope in these topics and keywords: cells, dna, inhibitor, tumor, pancreatic, induced, hereditary, genes, fusion, ferroptosisqa, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Scopus WOS
Categories: Oncology (Q1)
Price

4524 €

Inmediate OA

NPD

Embargoed OA

2262 €

Non OA

Metrics

Cancer Discovery

6,795

SJR Impact factor

163

H Index

384

Total Docs (Last Year)

1190

Total Docs (3 years)

6976

Total Refs

9083

Total Cites (3 years)

836

Citable Docs (3 years)

6,75

Cites/Doc (2 years)

18,17

Ref/Doc

Aims and Scope


cells, dna, inhibitor, tumor, pancreatic, induced, hereditary, genes, fusion, ferroptosisqa, inhibitorsforced, isoformselective, jak, kras, lipid, loss, lung, malignanciescnsderived, expression, entry, cycle, anchor, atm, bcell, biomarkersnf, biomedical, breast, cancer, cancerimproved, cancers, cancerthe, characterization, combination, convergence, agentbuying,



Best articles by citations

Gain-of-function genetic alterations of G9a drive oncogenesis

View more

Tumor-Promoting and -Suppressive Roles of Autophagy in the Same Mouse Model of BrafV600E-Driven Lung Cancer

View more

Insights into the Mechanism of Organ-Specific Cancer Metastasis

View more

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

View more

Social Interactomes for Enabling Research Communities

View more

Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes

View more

Haploinsufficiency of an RB-E2F1-Condensin II Complex Leads to Aberrant Replication and Aneuploidy

View more

Collateral Genome Instability by DNA Damage in Mitosis

View more

SPSB1 May Have MET Its Match during Breast Cancer Recurrence

View more

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models

View more

Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer

View more

Large-Scale Drug Screens Support Precision Medicine

View more
SHOW MORE ARTICLES

Predicting Cancer Drug Response: Advancing the DREAM

View more

BluepRINT for Moderate-to-Low Penetrance Cancer Susceptibility Genes Needed: Breast Cancer and Beyond

View more

Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas.

View more

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

View more

Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis

View more

Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges

View more

Adenoid Cystic Carcinoma Can Be Driven by MYB or MYBL1 Rearrangements: New Insights into MYB and Tumor Biology

View more

A Little pRB Can Lead to Big Problems

View more

Escaping Out of the Brain

View more

Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma

View more

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

View more

YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity

View more

Comments

No comments ... Be the first to comment!

FAQS